V铆ctor Albarr谩n-Artahona路 @vmalbarran 路 X路路 14 hours agoScore70
Body 路 original
Personalized cancer vaccines are becoming a clinical reality! 馃К
INTerpath-001: intismeran + pembrolizumab improves 2-year RFS in resected melanoma:
82.2% vs 70.0% (HR 0.58).
A major milestone for mRNA immunotherapy. Now awaiting mature OS data.
#ESMO26 @myESMO @OncoAlert
90 views 路 1 like 路 1 repost 路 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: V铆ctor Albarr谩n-Artahona 路 x.com